Document Detail


[Basic and clinical study of anticancer effect of etoposide on choriocarcinoma].
MedLine Citation:
PMID:  3385278     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
To establish a new method for treating choriocarcinoma, basic and clinical studies were made on Etoposide, a newly developed anticancer drug. I. Basic study 1) The crystal violet uptake sensitivity tests for anticancer drugs were examined with 5 human choriocarcinoma cell lines, BeWo, SCH, HCCM-5, JEG and SMT-CCl. 2) A drug concentration which could reduce the survival rate of SMT-CCl cells to 50% was regarded as the standard concentration. 3) Etoposide showed the same strong anticancer activity on all the choriocarcinoma cell lines as Act-D and CPA. II. Clinical study 1) In the treatment of trophoblastic diseases (choriocarcinoma 15 cases and invasive mole 14 cases), Etoposide therapy manifested a much higher effective rate (93.3%) than conventional Act-D therapy (50.0%) and MTX therapy (21.0%). But side effects of Etoposide therapy were milder than those of the other drugs. 2) Especially in the high risk choriocarcinoma group, the remission rate was 50% (PR 3, NC 2 and PD 1) for the conventional MAC protocol and 100% (CR 3 and PR 2) for the MECA protocol. In conclusion, it was demonstrated basically and clinically that Etoposide was very effective in the treatment of choriocarcinoma.
Authors:
T Fujii; M Maeda
Publication Detail:
Type:  English Abstract; Journal Article    
Journal Detail:
Title:  Nihon Sanka Fujinka Gakkai zasshi     Volume:  40     ISSN:  0300-9165     ISO Abbreviation:  Nippon Sanka Fujinka Gakkai Zasshi     Publication Date:  1988 May 
Date Detail:
Created Date:  1988-08-11     Completed Date:  1988-08-11     Revised Date:  2011-07-29    
Medline Journal Info:
Nlm Unique ID:  7505749     Medline TA:  Nihon Sanka Fujinka Gakkai Zasshi     Country:  JAPAN    
Other Details:
Languages:  jpn     Pagination:  593-600     Citation Subset:  IM    
Affiliation:
Department of Obstetrics and Gynecology, Hamamatsu University School of Medicine.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Choriocarcinoma / drug therapy*
Dactinomycin / administration & dosage
Drug Evaluation
Drug Screening Assays, Antitumor
Etoposide / pharmacology,  therapeutic use*
Female
Humans
Methotrexate / administration & dosage
Pregnancy
Remission Induction
Tumor Cells, Cultured / drug effects
Uterine Neoplasms / drug therapy*
Chemical
Reg. No./Substance:
33419-42-0/Etoposide; 50-76-0/Dactinomycin; 59-05-2/Methotrexate

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  [Significance of total hysterectomy in uterine cervical cancer persistent in the uterine cervix afte...
Next Document:  Quantitative description of subjective symptoms in pregnant women and their changes during the perin...